Pharvaris (NASDAQ:PHVS) Shares Down 4.9% - What's Next?

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) traded down 4.9% during trading on Friday . The stock traded as low as $17.09 and last traded at $17.03. 17,015 shares traded hands during trading, a decline of 76% from the average session volume of 71,186 shares. The stock had previously closed at $17.90.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald dropped their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and issued a $27.00 target price on shares of Pharvaris in a research note on Thursday, June 5th. Finally, Guggenheim assumed coverage on shares of Pharvaris in a research report on Wednesday, June 11th. They set a "buy" rating and a $32.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pharvaris currently has an average rating of "Buy" and an average price target of $36.20.

Pharvaris Price Performance

The firm has a 50-day moving average price of $16.79 and a two-hundred day moving average price of $16.67.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, sell-side analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after acquiring an additional 14,838 shares during the period. Deutsche Bank AG raised its stake in shares of Pharvaris by 13.0% in the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock valued at $348,000 after purchasing an additional 2,087 shares in the last quarter. Bank of America Corp DE lifted its position in Pharvaris by 205,286.7% in the fourth quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock worth $591,000 after purchasing an additional 30,793 shares during the period. JPMorgan Chase & Co. boosted its stake in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.